Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition
Published inInvestigative Ophthalmology & Visual Science, vol. 60, no. 7, p. 2764-2772
Publication date2019
Abstract
Keywords
- Adult
- Aged
- 80 and over
- Antineoplastic Agents/therapeutic use
- Benzimidazoles/therapeutic use
- Blotting
- Western
- Conjunctival Neoplasms/drug therapy/enzymology/pathology
- Female
- Fluorescent Antibody Technique
- Indirect
- Humans
- Imidazoles/therapeutic use
- Indazoles/therapeutic use
- Male
- Melanoma/drug therapy/enzymology/pathology
- Middle Aged
- Mitogen-Activated Protein Kinases/antagonists & inhibitors
- Molecular Targeted Therapy
- Phosphatidylinositol 3-Kinases/drug effects
- Protein Kinase Inhibitors/therapeutic use
- Proto-Oncogene Proteins B-raf/genetics
- Pyridones/therapeutic use
- Pyrimidinones/therapeutic use
- Quinolines/therapeutic use
- Sulfonamides/therapeutic use
- TOR Serine-Threonine Kinases/antagonists & inhibitors
- Tumor Cells
- Cultured
Affiliation
Research group
Citation (ISO format)
EL ZAOUI, Ikram et al. Conjunctival melanoma targeted therapy: MAPK and PI3K/mTOR pathways inhibition. In: Investigative Ophthalmology & Visual Science, 2019, vol. 60, n° 7, p. 2764–2772. doi: 10.1167/iovs.18-26508
Main files (1)
Article (Published version)
Identifiers
- PID : unige:134887
- DOI : 10.1167/iovs.18-26508
- PMID : 31247083
ISSN of the journal0146-0404
